New pill shows promise for tough stomach cancer in early trial

NCT ID NCT05489237

Ongoing Disease control Sponsor: IDRX, Inc., a wholly owned subsidiary of GSK, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This first-in-human study tests an experimental oral drug called IDRX-42 in 278 adults with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. All participants have already tried the standard drug imatinib without success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IDRX-42 (an oral drug taken once or twice daily)
What this could lead to: If successful, this could provide a new treatment option for people with advanced GIST whose cancer has stopped responding to standard therapy.
What could go wrong: This is a very early (Phase 1) trial, so the drug may not work or could have unexpected side effects. It is only for people who have already tried imatinib.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Digestive System Diseases digestive system disorder digestive system neoplasm gastrointestinal stromal tumor metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIGESTIVE SYSTEM DISEASE GASTROINTESTINAL DISEASES GASTROINTESTINAL NEOPLASMS GASTROINTESTINAL STROMAL TUMOR (GIST) METASTATIC CANCER

Contacts and locations

Locations

GSK Investigational Site

Miami, Florida, 33136, United States
GSK Investigational Site

Chicago, Illinois, 60611, United States
GSK Investigational Site

Boston, Massachusetts, 02215, United States
GSK Investigational Site

St Louis, Missouri, 63129, United States
GSK Investigational Site

New York, New York, 10065, United States
GSK Investigational Site

Portland, Oregon, 97239, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19111, United States
GSK Investigational Site

Houston, Texas, 77030, United States
GSK Investigational Site

Leuven, 3000, Belgium
GSK Investigational Site

Beijing, 100142, China
GSK Investigational Site

Guangzhou, China
GSK Investigational Site

Wuhan, 430022, China
GSK Investigational Site

Bordeaux, 33076, France
GSK Investigational Site

Lyon, France
GSK Investigational Site

Marseille, 13005, France
GSK Investigational Site

Villejuif, 94805, France
GSK Investigational Site

Berlin, Germany
GSK Investigational Site

Essen, 45122, Germany
GSK Investigational Site

Milan, 20133, Italy
GSK Investigational Site

Chiba, 277-8577, Japan
GSK Investigational Site

Kanagawa, 247-8533, Japan
GSK Investigational Site

Tokyo, 104-0045, Japan
GSK Investigational Site

Amsterdam, 1066 CX, Netherlands
GSK Investigational Site

Rotterdam, 3075 EA, Netherlands
GSK Investigational Site

Seongnam-si Gyeonggi-do, 463-707, South Korea
GSK Investigational Site

Seoul, 120-752, South Korea
GSK Investigational Site

Seoul, 5505, South Korea
GSK Investigational Site

Seoul, 6351, South Korea
GSK Investigational Site

Barcelona, Spain
GSK Investigational Site

Leeds, LS9 7TF, United Kingdom
GSK Investigational Site

London, SW3 6JJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.